Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bexagliflozin
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TheracosBio's BRENZAVVY is Non-Inferior to Dapagliflozin in Chinese T2D Patients
Details : Brenzavvy (bexagliflozin) is an FDA-approved oral sodium-glucose cotransporter 2 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Product Name : Brenzavvy
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 04, 2024
Lead Product(s) : Bexagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bexagliflozin
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : BAMCO Africa
Deal Size : Undisclosed
Deal Type : Partnership
TheracosBio and BAMCO Africa Partner for Affordable Diabetes Medication
Details : The partnership aims to bring Brenzavvy (bexagliflozin), an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes, to patients in Sub-Saharan Africa.
Product Name : Brenzavvy
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 17, 2024
Lead Product(s) : Bexagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : BAMCO Africa
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Bexagliflozin
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Independent Pharmacy Cooperative
Deal Size : Undisclosed
Deal Type : Partnership
IPC Secures Exclusive Distribution Rights for BRENZAVVY® with TheracosBio
Details : Under the agreement, IPC gains distribution rights for Brenzavvy (bexagliflozin), an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, used for adults with type 2 diabetes mellitus.
Product Name : Brenzavvy
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 02, 2024
Lead Product(s) : Bexagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Independent Pharmacy Cooperative
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Bexagliflozin
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : SmithRx
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, SmithRx will offer access to Brenzavvy (bexagliflozin), a sodium glucose transporter 2 (SGLT2) inhibitor and TheracosBio’s FDA-approved oral medication for adults with type 2 diabetes.
Product Name : Brenzavvy
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 17, 2023
Lead Product(s) : Bexagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : SmithRx
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Bexagliflozin
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brenzavvy (bexagliflozin), a SGLT2 inhibitor which helps in reducing renal reabsorption of filtered glucose and lowers the renal threshold for glucose, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diab...
Product Name : Brenzavvy
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 13, 2023
Lead Product(s) : Bexagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bexagliflozin
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brenzavvy™ (bexagliflozin) is a SGLT2 inhibitor thus, reducing renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
Product Name : Brenzavvy
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 23, 2023
Lead Product(s) : Bexagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bexagliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 11, 2022
Lead Product(s) : Bexagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bexagliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of THR-1442 Compared to Dapagliflozin as Add-on Therapy to Metformin in T2DM
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 16, 2021
Lead Product(s) : Bexagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bexagliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 15, 2018
Lead Product(s) : Bexagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bexagliflozin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 02, 2018
Lead Product(s) : Bexagliflozin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable